newsUnder its newly agreed acquisition, Sanofi is to acquire Inhibrx,…
24 January 2024 | By Catherine Eckford (European Pharmaceutical Review)
Under its newly agreed acquisition, Sanofi is to acquire Inhibrx, Inc., adding INBRX-101 to its portfolio, a therapy that could improve the treatment options available for alpha-1 antitrypsin deficiency (AATD).